Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06229353 · ClinicalTrials.gov registry record
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
A clinical trial, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- 34
- Enrollment target
NCT06229353: Clinical Trial study, sponsored by University of Alabama at Birmingham.
NCT06229353 is a clinical trial that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06229353 was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- 34 participants
- Enrollment target
Study Summary
To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it may be recommended under shared decision making, SDM).
Primary Outcome
HPV vaccination will be administered at the time of the study participant's initial visit (baseline)
Interventions
- BIOLOGICAL Gardasil 9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-07-30 |
Why NCT06229353 stopped before completion
NCT06229353 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gardasil 9 is the first listed.
NCT06229353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06229353 about?
NCT06229353 is a clinical study titled "Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department". To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate ...
What is the current status of trial NCT06229353?
This trial is currently terminated. The enrollment target is 34 participants. The study started on 2024-08-08. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06229353?
The interventions under investigation include: Gardasil 9 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06229353?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI